Abstract
Sotorasib is a selective, irreversible, oral small molecule covalent inhibitor of KRASG12C (OFF) recently approved in the U.S. for previously treated patients with KRASG12C NSCLC. RMC-4630 is a potent, selective, orally bioavailable allosteric inhibitor of SHP2, a protein tyrosine phosphatase functioning downstream of multiple RTKs as a convergent node in RAS signaling. RMC-4630 has demonstrated acceptable tolerability with an intermittent dosing schedule (Day 1 and Day 2 of each week) and single agent activity in KRASG12C NSCLC tumors in a phase 1b study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
